June 22, 2020 11:00 AM EDT

Looking at a groundbreaking advance, Myovant gets a priority review at FDA; Agenus, G1 forge new China deals

→ Just weeks after posting promising pivotal results for relugolix in prostate cancer, Myovant has picked up a

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Look­ing at a ground­break­ing ad­vance, My­ovant gets a pri­or­i­ty re­view at FDA; Agenus, G1 forge new Chi­na deals